Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Galecto Inc
Healthcare
P/NCAV
0.6x
Ticker
GLTO
Exchange
NASDAQ
Country
United States
Close
0.7 $
Mkt Cap
18.6M $
EV
-2.8M $
NCAV Burn Rate
41.2%
Current Ratio
6.31
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.1x
EV/FCF
0.1x
Dilution
1.6% p.A
Total Net Income
-238.9M $
Cheapness
96.0%
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average